When a spray-dried formulation falls short, whether due to poor bioavailability, scale-up limitations, or high pill burden, the path forward shouldn’t mean starting over. In this episode of The Top Line, AustinPx Chief Scientific Officer, Dr. Dave Miller unpacks what defines a “bad” formulation and, more importantly, how to pivot quickly without compromising timelines or program momentum.
Drawing on deep formulation and manufacturing expertise, Dr. Miller explores where traditional spray-dried approaches can fall short and how expanding the design space unlocks new possibilities. From optimizing drug loading to eliminating solvent-driven constraints, these strategies enable stronger clinical performance and more scalable outcomes.
The conversation also addresses how teams can seamlessly transition to improved formulations, even in late-stage development, while maintaining regulatory alignment and minimizing risk.
For developers navigating formulation roadblocks or planning for scale, this episode delivers a clear, practical path to move forward with confidence, and with better results.
The editorial staff had no role in this post’s creation.
